Published • loading... • Updated
Etentamig Shows Superior Efficacy vs SOC in Relapsed/Refractory Myeloma
Summary by cancernetwork.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
AbbVie Presents Positive Preliminary Results of Etentamig in Relapsed or Refractory Multiple Myeloma
AbbVie has announced positive preliminary results from the phase 3 study 'CERVINO', which show that etentamig significantly improved the response rate and progression-free survival in patients with relapsed or refractory multiple myeloma.
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
